Inhibition of endothelial cell activation by bHLH protein E2-2 and its impairment of angiogenesis

Blood

Volumn 115, Issue 20, 2010, Pages 4138-4147

  Tanaka, Aya ^a   Itoh, Fumiko ^a   Nishiyama, Koichi ^b   Takezawa, Toshiaki ^c   Kurihara, Hiroki ^b   Itoh, Susumu ^a   Kato, Mitsuyasu ^a  

^a UNIVERSITY OF TSUKUBA   (Japan)

^b UNIVERSITY OF TOKYO   (Japan)

^c NATIONAL INSTITUTE OF AGROBIOLOGICAL SCIENCES   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

BASIC HELIX LOOP HELIX TRANSCRIPTION FACTOR; CD31 ANTIGEN; COMPLEMENTARY DNA; DNA BINDING PROTEIN; E2 2 PROTEIN; GLUTATHIONE TRANSFERASE; LUCIFERASE; MATRIGEL; RNA; UNCLASSIFIED DRUG; VASCULOTROPIN RECEPTOR 2; BASIC HELIX LOOP HELIX LEUCINE ZIPPER TRANSCRIPTION FACTOR; ID1 PROTEIN, HUMAN; IDB1 PROTEIN, MOUSE; INHIBITOR OF DIFFERENTIATION 1; SMALL INTERFERING RNA; T CELL FACTOR PROTEIN; TCF4 PROTEIN, MOUSE; TCF7L2 TRANSCRIPTION FACTOR;

ADENOVIRUS; ANGIOGENESIS; ANIMAL CELL; ARTICLE; CELLULAR DISTRIBUTION; CONTROLLED STUDY; DNA BINDING; E BOX ELEMENT; ENDOTHELIUM CELL; ENZYME ACTIVITY; IMMUNOFLUORESCENCE; MOUSE; NONHUMAN; PLASMID; PRIORITY JOURNAL; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; ANIMAL; ANIMAL EMBRYO; CELL CULTURE; CELL STRAIN COS1; CERCOPITHECUS; CYTOLOGY; DRUG ANTAGONISM; FLUORESCENT ANTIBODY TECHNIQUE; GENETIC TRANSCRIPTION; GENETICS; HUMAN; IMMUNOPRECIPITATION; METABOLISM; NEOVASCULARIZATION (PATHOLOGY); PHYSIOLOGY; PROMOTER REGION; TWO HYBRID SYSTEM; VASCULAR ENDOTHELIUM; WESTERN BLOTTING;

ANIMALS; BASIC HELIX-LOOP-HELIX LEUCINE ZIPPER TRANSCRIPTION FACTORS; BLOTTING, WESTERN; CELLS, CULTURED; CERCOPITHECUS AETHIOPS; COS CELLS; EMBRYO, MAMMALIAN; ENDOTHELIUM, VASCULAR; FLUORESCENT ANTIBODY TECHNIQUE, INDIRECT; HUMANS; IMMUNOPRECIPITATION; INHIBITOR OF DIFFERENTIATION PROTEIN 1; MICE; NEOVASCULARIZATION, PATHOLOGIC; PROMOTER REGIONS, GENETIC; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RNA, SMALL INTERFERING; TCF TRANSCRIPTION FACTORS; TRANSCRIPTION, GENETIC; TWO-HYBRID SYSTEM TECHNIQUES; VASCULAR ENDOTHELIAL GROWTH FACTOR RECEPTOR-2;

EID: 77953266252     PISSN: 00064971     EISSN: 15280020     Source Type: Journal    
DOI: 10.1182/blood-2009-05-223057     Document Type: Article

References (54)

1. Carmeliet P. Angiogenesis in life, disease and medicine. Nature. 2005;438(7070):932-936.
2. Adams RH, Alitalo K. Molecular regulation of angiogenesis and lymphangiogenesis. Nat Rev Mol Cell. Biol. 2007;8(6):464-478.
3. Perk J, Iavarone A, Benezra R. Id family of helix-loop- helix proteins in cancer. Nat Rev Cancer. 2005;5(8):603-614. (Pubitemid 41081386)
4. Lasorella A, Noseda M, Beyna M, Yokota Y, Iavarone A. Id2 is a retinoblastoma protein target and mediates signalling by Myc oncoproteins. Nature. 2000;407(6804):592-598.
5. Ohtani N, Zebedee Z, Huot TJ, et al. Opposing effects of Ets and Id proteins on p16INK4a expression during cellular senescence. Nature. 2001;409(6823):1067-1070. (Pubitemid 32204062)
6. Benezra R, Davis RL, Lockshon D, Turner DL, Weintraub H. The protein Id: a negative regulator of helix-loop-helix DNA binding proteins. Cell. 1990;61(1):49-59. (Pubitemid 20134378)
7. Jen Y, Weintraub H, Benezra R. Overexpression of Id protein inhibits the muscle differentiation program: in vivo association of Id with E2A proteins. Genes Dev. 1992;6(8):1466-1479.
8. Langlands K, Yin X, Anand G, Prochownik EV. Differential interactions of Id proteins with basichelix- loop-helix transcription factors. J Biol Chem. 1997;272(32):19785-19793. (Pubitemid 27340071)
9. Ying QL, Nichols J, Chambers I, Smith A. BMP induction of Id proteins suppresses differentiation and sustains embryonic stem cell self-renewal in collaboration with STAT3. Cell. 2003;115(3):281-292. (Pubitemid 37487702)
10. Hollnagel A, Oehlmann V, Heymer J, Ruther U, Nordheim A. Id genes are direct targets of bone morphogenetic protein induction in embryonic stem cells. J Biol Chem. 1999;274(28):19838-19845. (Pubitemid 129519434)
11. Nakashima K, Takizawa T, Ochiai W, et al. BMP2-mediated alteration in the developmental pathway of fetal mouse brain cells from neurogenesis to astrocytogenesis. Proc Natl Acad Sci U S A. 2001;98(10):5868-5873. (Pubitemid 32435734)
12. Katagiri T, Yamaguchi A, Komaki M, et al. Bone morphogenetic protein-2 converts the differentiation pathway of C2C12 myoblasts into the osteoblast lineage. J Cell Biol. 1994;127(6):1755-1766.
13. Lopez-Rovira T, Chalaux E, Massagué J, Rosa JL, Ventura F. Direct binding of Smad1 and Smad4 to two distinct motifs mediates bone morphogenetic protein-specific transcriptional activation of Id1 gene. J Biol Chem. 2002;277(5):3176-3185.
14. Ogata T, Wozney JM, Benezra R, Noda M. Bone morphogenetic protein 2 transiently enhances expression of a gene, Id (inhibitor of differentiation), encoding a helix-loop-helix molecule in osteoblast-like cells. Proc Natl Acad Sci U S A. 1993;90(19):9219-9222.
15. Kowanetz M, Valcourt U, Bergström R, Heldin C-H, Moustakas A. Id2 and Id3 define the potency of cell proliferation and differentiation responses to transforming growth factor β and bone morphogenetic protein. Mol Cell Biol. 2004;24(10):4241-4254.
16. Lyden D, Young AZ, Zagzag D, et al. Id1 and Id3 are required for neurogenesis, angiogenesis and vascularization of tumour xenografts. Nature. 1999;401(6754):670-677.
17. Goumans M-J, Valdimarsdottir G, Itoh S, Rosendahl A, Sideras P, ten Dijke P. Balancing the activation state of the endothelium via two distinct TGFβ type I receptors. EMBO J. 2002;21(7):1743-1753.
18. Valdimarsdottir G, Goumans M-J, Rosendahl A, et al. Stimulation of Id1 expression by bone morphogenetic protein is sufficient and necessary for bone morphogenetic protein-induced activation of endothelial cells. Circulation. 2002;106(17):2263-2270.
19. Ruzinova MB, Schoer RA, Gerald W, et al. Effect of angiogenesis inhibition by Id loss and the contribution of bone-marrow-derived endothelial cells in spontaneous murine tumors. Cancer Cell. 2003;4(4):277-289.
20. Itoh F, Itoh S, Goumans M-J, et al. Synergy and antagonism between Notch and BMP receptor signaling pathways in endothelial cells. EMBO J. 2004;23(3):541-551.
21. Lazorchak A, Jones ME, Zhuang Y. New insights into E-protein function in lymphocyte development. Trends Immunol. 2005;26(6):334-338.
22. Sun XH. Multitasking of helix-loop-helix proteins in lymphopoiesis. Adv Immunol. 2004;84:43-77.
23. Murre C. Helix-loop-helix proteins and lymphocyte development. Nat Immunol. 2005;6(11):1079-1086.
24. Einarson MB, Chao MV. Regulation of Id1 and its association with basic helix-loop-helix proteins during nerve growth factor-induced differentiation of PC12 cells. Mol Cell Biol. 1995;15(8):4175-4183.
25. Puri PL, Sartorelli V. Regulation of muscle regulatory factors by DNA-binding, interacting proteins, and post-transcriptional modifications. J Cell Physiol. 2000;185(2):155-173.
26. Tanaka A, Itoh F, Itoh S, Kato M. TAL1/SCL relieves the E2-2-mediated repression of VEGFR2 promoter activity. J Biochem. 2009;145(2):129-135.
27. Ema M, Faloon P, Zhang WJ, et al. Combinatorial effects of Flk1 and Tal1 on vascular and hematopoietic development in the mouse. Genes Dev. 2003;17(3):380-393.
28. Kawabata M, Inoue H, Hanyu A, Imamura T, Miyazono K. Smad proteins exist as monomers in vivo and undergo homo- and hetero-oligomerization upon activation by serine/threonine kinase receptors. EMBO J. 1998;17(14):4056-4065.
29. Goldman LA, Cutrone EC, Kotenko SV, Krause CD, Langer JA. Modifications of vectors pEF-BOS, pcDNA1 and pcDNA3 result in improved convenience and expression. Biotechniques. 1996;21(6):1013-1015.
30. Sigvardsson M. Overlapping expression of early B-cell factor and basic helix-loop-helix proteins as a mechanism to dictate B-lineage-specific activity of the 5 promoter. Mol Cell Biol. 2000;20(10):3640-3654.
31. Holderfield MT, Henderson Anderson AM, Kokubo H, et al. HESR1/CHF2 suppresses VEGFR2 transcription independent of binding to E-boxes. Biochem Biophys Res Commun. 2006;346(3):637-648.
32. He T-C, Zhou S, da Costa LT, Yu J, Kinzler KW, Vogelstein B. A simplified system for generating recombinant adenoviruses. Proc Natl Acad Sci U S A. 1998;95(5):2509-2514.
33. Takezawa T, Takenouchi T, Imai K, Takahashi T, Hashizume K. Cell culture on thin tissue sections commonly prepared for histopathology. FASEB J. 2002;16(13):1847-1849.
34. Itoh F, AsaoH, Sugamura K, Heldin C-H, ten Dijke P, Itoh S. Promoting bone morphogenetic protein signaling through negative regulation of inhibitory Smads. EMBO J. 2001;20(15):4132-4142.
35. Kano MR, Morishita Y, Iwata C, et al. VEGF-A and FGF-2 synergistically promote neoangiogenesis through enhancement of endogenous PDGF-B-PDGFRβ signaling. J Cell Sci. 2005;118(16):3759-3768.
36. Yamada Y, Pannell R, Forster A, Rabbitts TH. The oncogenic LIM-only transcription factor Lmo2 regulates angiogenesis but not vasculogenesis in mice. Proc Natl Acad Sci U S A. 2000;97(1):320-324.
37. Lazrak M, Deleuze V, Noel D, et al. The bHLH TAL-1/SCL regulates endothelial cell migration and morphogenesis. J Cell Sci. 2004;117(7):1161-1171.
38. Deleuze V, Chalhoub E, El-Hajj R, et al. TAL-1/ SCL and its partners E47 and LMO2 up-regulate VE-cadherin expression in endothelial cells. Mol Cell Biol. 2007;27(7):2687-2697.
39. Korchynskyi O, ten Dijke P. Identification and functional characterization of distinct critically important bone morphogenetic protein-specific response elements in the Id1 promoter. J Biol Chem. 2002;277(7):4883-4891.
40. Skurk C, Maatz H, Rocnik E, Bialik A, Force T, Walsh K. Glycogen-synthase kinase3β/β-catenin axis promotes angiogenesis through activation of vascular endothelial growth factor signaling in endothelial cells. Cir Res. 2005;96(3):308-318.
41. Olsson AK, Dimberg A, Kreuger J, Claesson-Welsh L. VEGF receptor signaling: in control of vascular function. Nat Rev Mol Cell Biol. 2006;7(5):359-371.
42. 1-mediated inhibition of the flk- 1/KDR gene is mediated by a 5′-untranslated region palindromic GATA site. J Biol Chem. 2001;276(7):5395-5402.
43. Zhuang Y, Soriano P, Weintraub H. The helix-loop- helix gene E2A is required for B cell formation. Cell. 1994;79(5):875-884.
44. Bain G, Maandag EC, Izon DJ, et al. E2A proteins are required for proper B cell development and initiation of immunoglobulin gene rearrangements. Cell. 1994;79(5):885-892.
45. Bain G, Quong MW, Soloff RS, Hedrick SM, Murre C. Thymocyte maturation is regulated by the activity of the helix-loop-helix protein, E47. J Exp Med. 1999;190(11):1605-1616.
46. Liu Y, Ray SK, Yang X-Q, Luntz-Leybman V, Chiu I-M. A splice variant of E2-2 basic helix-loop-helix protein represses the brain-specific fibroblast growth factor 1 promoter through the binding to an imperfect E-box. J Biol Chem. 1998;273(30):19269-19276.
47. Markus M, Du Z, Benezra R. Enhancer-specific modulation of E protein activity. J Biol Chem. 2002;277(8):6469-6477.
48. Jackson TA, Taylor HE, Sharma D, Desiderio S, Danoff SK. Vascular endothelial growth factor receptor-2: counter-regulation by the transcription factors, TFII-I and TFII-IRD1. J Biol Chem. 2005;280(33):29856-29863.
49. Kappel A, Schlaeger TM, Flamme I, Orkin SH, Risau W, Breier G. Role of SCL/Tal-1, GATA, and Ets transcription factor binding sites for the regulation of Flk-1 expression during murine vascular development. Blood. 2000;96(9):3078-3085.
50. Patterson C, Perrella MA, Hsieh CM, Yoshizumi M, Lee ME, Haber E. Cloning and functional analysis of the promoter for KDR/flk-1, a receptor for vascular endothelial growth factor. J Biol Chem. 1995;270(39):23111-23118.
51. Hata Y, Duh E, Zhang K, Robinson GS, Aiello LP. Transcription factors Sp1 and Sp3 alter vascular endothelial growth factor receptor expression through a novel recognition sequence. J Biol Chem. 1998;273(30):19294-19303.
52. Illi B, Puri P, Morgante L, Capogrossi MC, Gaetano C. Nuclear factor-κB and cAMP response element binding protein mediate opposite transcriptional effects on the Flk-1/KDR gene promoter. Circ Res. 2000;86(12):E110-E117.
53. Nishiyama K, Takaji K, Uchijima Y et al. Protein kinase A-regulated nucleocytoplasmic shuttling of Id1 during angiogenesis. J Biol Chem. 2007;282(23):17200-17209.
54. Zhuang Y, Cheng P, Weintraub H. B-lymphocyte development is regulated by the combined dosage of three basic helix-loop-helix genes, E2A, E2-2 and HEB. Mol Cell Biol. 1996;16(6):2898-2905.